Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research Letter

Invasive Candida bovina Infection, France

Kévin BrunetComments to Author , Alida Minoza, Blandine Rammaert, Vincent Portet-Sulla, Florent Hubert, Jean-Claude Lorenzo, Marie-Hélène Rodier, and Estelle Cateau
Author affiliations: Poitiers University Hospital, Poitiers, France (K. Brunet, A. Minoza, B. Rammaert, V. Portet-Sulla, F. Hubert, J.-C. Lorenzo, M.-H. Rodier, E. Cateau); INSERM U1070, Poitiers (K. Brunet, B. Rammaert); University of Poitiers, Poitiers (K. Brunet, B. Rammaert, M.-H. Rodier, E. Cateau); CNRS 7267, Poitiers (M.-H. Rodier, E. Cateau)

Main Article


Antifungal susceptibility of Candida bovina from a patient in France, evaluated by using EUCAST broth microdilution*

Antifungal agent MIC, mg/L
Fluconazole 2
Posaconazole ≤0.016
Voriconazole 0.03
Isavuconazole 0.015
Amphotericin B 0.03
Caspofungin 0.06
Micafungin 0.03

*EUCAST, European Committee on Antimicrobial Susceptibility Testing.

Main Article

Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.